Colorectal cancer remains one of the most preventable causes of cancer death, yet millions of eligible adults remain unscreened. Increasing participation requires more than recommending screening—it requires offering evidence-based options that meet patients where they are. This session explores how emerging stool-based screening technologies are expanding patient choice while maintaining strong clinical performance and integrating into routine care. Attendees will learn how recent updates to national clinical guidelines, growing commercial and Medicare coverage, and implementation through national laboratory infrastructure are accelerating access to innovative screening options. The discussion will also examine how organizations can prepare for the future of quality measurement by adopting scalable, interoperable screening strategies that support population health management, close gaps in care, and improve follow-up after positive results. Participants will leave with a practical understanding of how innovation in colorectal cancer screening can complement existing quality improvement efforts while positioning health plans and health systems for the next evolution of quality measurement.

Sponsored by

ColoSense